A Phase 2 interventional study of AZD0780 and Placebo in Dyslipidemia, sponsored by AstraZeneca. Completed at 55 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-17.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing laroprovstat in Dyslipidemias — none open to participants now, 1 under way, 1 of them phase 3. laroprovstat · Dyslipidemias.
Among the 11 studies testing laroprovstat in Dyslipidemias, this one is the 2nd largest by enrollment, is one of 4 that started in 2024, is one of 2 in phase 2, and was the 4th registered.
1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →None of the 11 studies testing laroprovstat in Dyslipidemias is open now. The open studies under Dyslipidemias, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 1
First in 2022; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 428 is above the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Median enrollment 59 across the 11 interventional studies. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 1 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
57 studies in Dyslipidemias by AstraZeneca: 1 open now, 3 under way, 1 of them phase 3. Of 52 finished, 11 (21%) have results posted.
Among the 57 studies in Dyslipidemias by AstraZeneca, this one is the 13th largest by enrollment of the 37 interventional ones that give a count, is one of 5 that started in 2024, is one of 3 in phase 2, and was the 46th registered.
AstraZeneca’s Dyslipidemias studies by the year they started, since 2002.
1 of the studies testing laroprovstat in Dyslipidemias that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06834932Phase 3AstraZenecaA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia | 2027-02-22 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing laroprovstat in Dyslipidemias, from their registry updates:
Among AstraZeneca’s 57 in Dyslipidemias:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to measure the effect of different daily doses of AZD0780 on Low-Density Lipoprotein (LDL-C) levels compared with placebo in participants with dyslipidemia. The effect of AZD0780 versus placebo on other lipid parameters and inflammatory markers is also investigated. The concentration of AZD0780 in blood at specific timepoints is measured, and the safety and tolerability of AZD0780 will be evaluated. There is a follow-up after end of treatment, but expanded access is not available. The primary hypothesis is that at least one of the investigated doses of AZD0780 is superior to placebo in lowering LDL-C level, in percent change from baseline up to week 12.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AZD0780, Dose 1
Drug: AZD0780
AZD0780, Dose 2
Drug: AZD0780
AZD0780, Dose 3
Drug: AZD0780
AZD0780, Dose 4
Drug: AZD0780
Placebo, matched for appearance
Drug: Placebo
AZD0780 administered orally, once daily for 12 weeks
Placebo administered orally, once daily for 12 weeks
Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12
Percent change was calculated as (Week 12 LDL-C - Baseline LDL-C) / Baseline LDL-C \* 100. Negative values indicate reduction in LDL-C. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.
Time frame: From first day of treatment up to week 12
Percent Change From Baseline of Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12
Percent change was calculated as (Week 12 LDL-C - Baseline LDL-C) / Baseline LDL-C \* 100. Negative values indicate reduction in LDL-C. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.
Time frame: From first day of treatment up to week 12
Percent Change From Baseline of Total Cholesterol at Week 12
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.
Time frame: From first day of treatment up to week 12
Percent Change From Baseline of High-Density Lipoprotein Cholesterol (HDL-C) at Week 12
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.
Time frame: From first day of treatment up to week 12
Percent Change From Baseline of Triglycerides at Week 12
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.
Time frame: From first day of treatment up to week 12
Percent Change From Baseline of Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.
Time frame: From first day of treatment up to week 12
Percent Change From Baseline of Very-Low-Density Lipoprotein Cholesterol (VLDL-C) at Week 12
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.
Time frame: From first day of treatment up to week 12
Percent Change From Baseline of Apolipoprotein A1 at Week 12
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.
Time frame: From first day of treatment up to week 12
Percent Change From Baseline of Apolipoprotein B at Week 12
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.
Time frame: From first day of treatment up to week 12
Percent Change From Baseline of Total Cholesterol at Week 12
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.
Time frame: From first day of treatment up to week 12
Percent Change From Baseline of High-Density Lipoprotein Cholesterol (HDL-C) at Week 12
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.
Time frame: From first day of treatment up to week 12
Percent Change From Baseline of Triglycerides at Week 12
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.
Time frame: From first day of treatment up to week 12
Percent Change From Baseline of Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.
Time frame: From first day of treatment up to week 12
Percent Change From Baseline of Very-Low-Density Lipoprotein Cholesterol (VLDL-C) at Week 12
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.
Time frame: From first day of treatment up to week 12
Percent Change From Baseline of Apolipoprotein A1 at Week 12
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.
Time frame: From first day of treatment up to week 12
Percent Change From Baseline of Apolipoprotein B at Week 12
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.
Time frame: From first day of treatment up to week 12
Percent Change From Baseline of Lipoprotein-a at Week 12
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Descriptive statistics only.
Time frame: From first day of treatment up to week 12
Percent Change From Baseline of Remnant Cholesterol at Week 12
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Descriptive statistics only.
Time frame: From first day of treatment up to week 12
Percent Change From Baseline of High Sensitivity C-reactive Protein (hsCRP) at Week 12
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Descriptive statistics only.
Time frame: From first day of treatment up to week 12
AZD0780 Plasma Concentrations Summarized by Sampling Timepoint
Geometric mean plasma concentration; LLOQ = 0.01 umol/L; BLQ values are handled as Not Quantified (NQ)
Time frame: From week 1 up to week 12
The study was conducted from January 2024 to September 2024 in 55 research sites in 8 countries (United States, Canada, Czech Republic, Denmark, Hungary, Japan, Slovakia, and Spain).
| Milestone | AZD0780 1 mg | AZD0780 3 mg | AZD0780 10 mg | AZD0780 30 mg | Placebo |
|---|---|---|---|---|---|
| Started | 86 | 85 | 85 | 85 | 87 |
| Started treatment | 86 | 85 | 84 | 85 | 86 |
| Completed | 81 | 81 | 84 | 80 | 82 |
| Not completed | 5 | 4 | 1 | 5 | 5 |
| Withdrew: Adverse event | 1 | 0 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 2 |
| Withdrew: Protocol violation | 0 | 2 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 1 | 1 |
| Withdrew: Non-compliance with study drug | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Screen failure | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Other | 2 | 1 | 0 | 2 | 0 |
Percent change was calculated as (Week 12 LDL-C - Baseline LDL-C) / Baseline LDL-C \* 100. Negative values indicate reduction in LDL-C. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.
| Percent Change (%) | AZD0780 1 mg | AZD0780 3 mg | AZD0780 10 mg | AZD0780 30 mg | Placebo |
|---|---|---|---|---|---|
| Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 | -31.19 (-37.06 to -25.32) | -33.83 (-39.78 to -27.88) | -41.09 (-46.92 to -35.25) | -46.62 (-52.48 to -40.76) | 4.08 (-1.84 to 10.00) |
Percent change was calculated as (Week 12 LDL-C - Baseline LDL-C) / Baseline LDL-C \* 100. Negative values indicate reduction in LDL-C. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.
| Percent Change (%) | AZD0780 1 mg | AZD0780 3 mg | AZD0780 10 mg | AZD0780 30 mg | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline of Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12 | -30.47 (-36.45 to -24.49) | -33.35 (-39.44 to -27.26) | -40.47 (-46.42 to -34.53) | -46.41 (-52.48 to -40.35) | 3.39 (-2.63 to 9.40) |
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.
| Percent Change (%) | AZD0780 1 mg | AZD0780 3 mg | AZD0780 10 mg | AZD0780 30 mg | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline of Total Cholesterol at Week 12 | -18.93 (-22.48 to -15.38) | -20.09 (-23.70 to -16.48) | -24.84 (-28.36 to -21.32) | -27.06 (-30.62 to -23.51) | 2.29 (-1.29 to 5.88) |
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.
| Percent Change (%) | AZD0780 1 mg | AZD0780 3 mg | AZD0780 10 mg | AZD0780 30 mg | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline of High-Density Lipoprotein Cholesterol (HDL-C) at Week 12 | 0.12 (-2.96 to 3.19) | 4.03 (0.93 to 7.12) | 1.97 (-1.07 to 5.00) | 4.66 (1.60 to 7.72) | 3.65 (0.58 to 6.71) |
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.
| Percent Change (%) | AZD0780 1 mg | AZD0780 3 mg | AZD0780 10 mg | AZD0780 30 mg | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline of Triglycerides at Week 12 | 3.06 (-5.05 to 11.17) | 2.90 (-5.29 to 11.08) | 1.93 (-5.99 to 9.85) | -0.44 (-8.52 to 7.63) | 9.56 (1.47 to 17.65) |
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.
| Percent Change (%) | AZD0780 1 mg | AZD0780 3 mg | AZD0780 10 mg | AZD0780 30 mg | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline of Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12 | -26.85 (-32.65 to -21.04) | -29.86 (-35.75 to -23.97) | -35.13 (-40.92 to -29.35) | -41.65 (-47.45 to -35.85) | 3.53 (-2.33 to 9.39) |
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.
| Percent Change (%) | AZD0780 1 mg | AZD0780 3 mg | AZD0780 10 mg | AZD0780 30 mg | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline of Very-Low-Density Lipoprotein Cholesterol (VLDL-C) at Week 12 | 1.13 (-6.55 to 8.81) | 4.02 (-3.69 to 11.73) | 2.21 (-5.26 to 9.68) | 0.46 (-7.15 to 8.07) | 7.19 (-0.52 to 14.90) |
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.
| Percent Change (%) | AZD0780 1 mg | AZD0780 3 mg | AZD0780 10 mg | AZD0780 30 mg | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline of Apolipoprotein A1 at Week 12 | 1.67 (-1.00 to 4.34) | 3.25 (0.58 to 5.93) | 3.61 (1.02 to 6.21) | 5.72 (3.08 to 8.36) | 4.46 (1.80 to 7.12) |
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Hypothetical estimand: data collected after intercurrent events (ICEs) defined in the CSP excluded.
| Percent Change (%) | AZD0780 1 mg | AZD0780 3 mg | AZD0780 10 mg | AZD0780 30 mg | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline of Apolipoprotein B at Week 12 | -24.08 (-28.37 to -19.80) | -25.39 (-29.71 to -21.07) | -34.33 (-38.53 to -30.12) | -36.95 (-41.20 to -32.71) | 2.92 (-1.39 to 7.23) |
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.
| Percent Change (%) | AZD0780 1 mg | AZD0780 3 mg | AZD0780 10 mg | AZD0780 30 mg | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline of Total Cholesterol at Week 12 | -18.23 (-21.88 to -14.58) | -19.80 (-23.54 to -16.07) | -24.54 (-28.14 to -20.94) | -26.90 (-30.60 to -23.20) | 1.73 (-1.88 to 5.34) |
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.
| Percent Change (%) | AZD0780 1 mg | AZD0780 3 mg | AZD0780 10 mg | AZD0780 30 mg | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline of High-Density Lipoprotein Cholesterol (HDL-C) at Week 12 | 0.80 (-2.29 to 3.89) | 3.66 (0.58 to 6.75) | 2.17 (-0.85 to 5.19) | 4.65 (1.61 to 7.70) | 3.11 (0.11 to 6.12) |
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.
| Percent Change (%) | AZD0780 1 mg | AZD0780 3 mg | AZD0780 10 mg | AZD0780 30 mg | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline of Triglycerides at Week 12 | 2.81 (-5.25 to 10.86) | 2.17 (-5.93 to 10.28) | 1.72 (-6.09 to 9.54) | -0.83 (-8.87 to 7.22) | 9.04 (1.16 to 16.92) |
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.
| Percent Change (%) | AZD0780 1 mg | AZD0780 3 mg | AZD0780 10 mg | AZD0780 30 mg | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline of Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12 | -26.13 (-31.94 to -20.32) | -29.42 (-35.34 to -23.49) | -34.77 (-40.59 to -28.95) | -41.35 (-47.27 to -35.43) | 2.86 (-2.91 to 8.62) |
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.
| Percent Change (%) | AZD0780 1 mg | AZD0780 3 mg | AZD0780 10 mg | AZD0780 30 mg | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline of Very-Low-Density Lipoprotein Cholesterol (VLDL-C) at Week 12 | 0.81 (-6.81 to 8.43) | 2.67 (-4.91 to 10.26) | 1.77 (-5.59 to 9.13) | 0.42 (-7.18 to 8.02) | 6.74 (-0.68 to 14.15) |
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.
| Percent Change (%) | AZD0780 1 mg | AZD0780 3 mg | AZD0780 10 mg | AZD0780 30 mg | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline of Apolipoprotein A1 at Week 12 | 2.52 (-0.18 to 5.22) | 2.89 (0.14 to 5.64) | 3.79 (1.19 to 6.39) | 5.55 (2.88 to 8.22) | 3.82 (1.15 to 6.48) |
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Treatment policy estimand: data collected after ICEs defined in the CSP retained.
| Percent Change (%) | AZD0780 1 mg | AZD0780 3 mg | AZD0780 10 mg | AZD0780 30 mg | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline of Apolipoprotein B at Week 12 | -23.35 (-27.79 to -18.91) | -24.53 (-29.06 to -19.99) | -33.85 (-38.18 to -29.51) | -36.86 (-41.35 to -32.37) | 2.44 (-2.00 to 6.89) |
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Descriptive statistics only.
| Percent Change (%) | AZD0780 1 mg | AZD0780 3 mg | AZD0780 10 mg | AZD0780 30 mg | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline of Lipoprotein-a at Week 12 | -7.48 (-64.6 to 319.6) | -11.16 (-56.7 to 2582.3) | -19.57 (-66.3 to 36.6) | -19.43 (-71.3 to 55.6) | 0.00 (-46.3 to 98.9) |
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Descriptive statistics only.
| Percent Change (%) | AZD0780 1 mg | AZD0780 3 mg | AZD0780 10 mg | AZD0780 30 mg | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline of Remnant Cholesterol at Week 12 | -9.09 (-77.8 to 160.0) | -8.33 (-169.7 to 671.4) | -22.95 (-1200.0 to 266.7) | -18.31 (-200.0 to 420.0) | -5.00 (-85.7 to 558.3) |
Percent change was calculated as (Week 12 value - Baseline value) / Baseline value \* 100. Negative values indicate reduction in lipid parameter. Baseline is the last non-missing value prior to first administration of study treatment. Descriptive statistics only.
| Percent Change (%) | AZD0780 1 mg | AZD0780 3 mg | AZD0780 10 mg | AZD0780 30 mg | Placebo |
|---|---|---|---|---|---|
| Percent Change From Baseline of High Sensitivity C-reactive Protein (hsCRP) at Week 12 | 0.00 (-96.8 to 2500.0) | 0.00 (-79.8 to 716.7) | 0.00 (-98.1 to 4950.0) | -22.22 (-93.3 to 2603.0) | 0.00 (-75.7 to 1358.3) |
Geometric mean plasma concentration; LLOQ = 0.01 umol/L; BLQ values are handled as Not Quantified (NQ)
| umol/L | AZD0780 1 mg | AZD0780 3 mg | AZD0780 10 mg | AZD0780 30 mg |
|---|---|---|---|---|
| Week 1 | 0.0790 ± 76.7603 | 0.2523 ± 54.0463 | 0.8120 ± 72.6051 | 2.6420 ± 58.0213 |
| Week 2 | 0.0926 ± 71.7485 | 0.2639 ± 75.6804 | 0.8156 ± 95.1545 | 2.6676 ± 55.8538 |
| Week 4 | 0.0901 ± 81.2970 | 0.2380 ± 98.8448 | 0.8393 ± 74.6636 | 2.7059 ± 47.5671 |
| Week 8 | 0.0932 ± 68.6270 | 0.2359 ± 102.5351 | 0.8350 ± 92.9640 | 2.4911 ± 102.6420 |
| Week 12 | 0.0957 ± 61.8573 | 0.2317 ± 111.2636 | 0.7221 ± 119.9436 | 2.4373 ± 134.1014 |
Collected over Adverse events were collected from start of study treatment, throughout the 12-week treatment period, and the 2-weeks follow-up period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AZD0780 1 mg | 0/86 (0%) | 2/86 (2.3%) | 4/86 (4.7%) |
| AZD0780 3 mg | 0/85 (0%) | 2/85 (2.4%) | 2/85 (2.4%) |
| AZD0780 10 mg | 0/84 (0%) | 2/84 (2.4%) | 2/84 (2.4%) |
| AZD0780 30 mg | 0/85 (0%) | 1/85 (1.2%) | 3/85 (3.5%) |
| Placebo | 0/86 (0%) | 0/86 (0%) | 5/86 (5.8%) |
| Event | AZD0780 1 mg | AZD0780 3 mg | AZD0780 10 mg | AZD0780 30 mg | Placebo |
|---|---|---|---|---|---|
| OsteomyelitisInfections and infestations | 0/86 | 0/85 | 1/84 | 0/85 | 0/86 |
| Lentigo malignaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/86 | 0/85 | 1/84 | 0/85 | 0/86 |
| Colonic abscessInfections and infestations | 0/86 | 1/85 | 0/84 | 0/85 | 0/86 |
| Transient ischaemic attackNervous system disorders | 0/86 | 0/85 | 0/84 | 1/85 | 0/86 |
| Inguinal herniaGastrointestinal disorders | 0/86 | 1/85 | 0/84 | 0/85 | 0/86 |
| Major DepressionPsychiatric disorders | 1/86 | 0/85 | 0/84 | 0/85 | 0/86 |
| SyncopeNervous system disorders | 1/86 | 0/85 | 0/84 | 0/85 | 0/86 |
| Angina pectorisCardiac disorders | 1/86 | 0/85 | 0/84 | 0/85 | 0/86 |
| Event | AZD0780 1 mg | AZD0780 3 mg | AZD0780 10 mg | AZD0780 30 mg | Placebo |
|---|---|---|---|---|---|
| HypertensionVascular disorders | 4/86 | 2/85 | 2/84 | 3/85 | 5/86 |
| Age, Categorical(Participants) | AZD0780 1 mg | AZD0780 3 mg | AZD0780 10 mg | AZD0780 30 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 47 | 59 | 39 | 50 | 47 | 242 |
| >=65 years | 39 | 26 | 45 | 35 | 39 | 184 |
| Age, Continuous(Years) | AZD0780 1 mg | AZD0780 3 mg | AZD0780 10 mg | AZD0780 30 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 62.7 ± 7.9 | 60.9 ± 7.2 | 63.9 ± 7.2 | 62.3 ± 7.9 | 62.3 ± 7.8 | 62.4 ± 7.6 |
| Sex: Female, Male(Participants) | AZD0780 1 mg | AZD0780 3 mg | AZD0780 10 mg | AZD0780 30 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 41 | 41 | 37 | 41 | 44 | 204 |
| Male | 45 | 44 | 47 | 44 | 42 | 222 |
| Ethnicity (NIH/OMB)(Participants) | AZD0780 1 mg | AZD0780 3 mg | AZD0780 10 mg | AZD0780 30 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 5 | 10 | 6 | 12 | 8 | 41 |
| Not Hispanic or Latino | 81 | 75 | 78 | 73 | 78 | 385 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | AZD0780 1 mg | AZD0780 3 mg | AZD0780 10 mg | AZD0780 30 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 0 | 1 |
| Asian | 8 | 6 | 6 | 6 | 6 | 32 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 5 | 3 | 4 | 4 | 6 | 22 |
| White | 73 | 75 | 73 | 74 | 73 | 368 |
| More than one race | 0 | 0 | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 | 0 | 2 |
| Low-Density Lipoprotein Cholesterol (LDL-C)(mmol/L) | AZD0780 1 mg | AZD0780 3 mg | AZD0780 10 mg | AZD0780 30 mg | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 2.6822 ± 0.6918 | 2.7258 ± 0.8960 | 2.4784 ± 0.7122 | 2.5500 ± 0.6939 | 2.5769 ± 0.6620 | 2.6031 ± 0.7378 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
Ran from Jan 2024 to primary completion in Sep 2024, 8 months.
Results were first posted in Nov 2025, 1 year 1 month after primary completion.
Of 35 industry-sponsored phase 2 interventional studies under Dyslipidemias, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 8 months is below that.
Counting every sponsor, half of 43 studies reached it within 13 months; a quarter within 7 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Laroprovstat